We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Evaluation of the management of PARP inhibitor toxicities in ovarian and endometrial cancer within a multi-institution health-system.
- Authors
Hatch, Rachel V; Patel, Sweta U; Cambareri, Christine; Uritsky, Tanya; Martin, Lainie P
- Abstract
Introduction: Poly-adenosine diphosphate ribose polymerase inhibitors (PARPi) have become a cornerstone of therapy in the management ovarian cancer and other cancers. PARPi are associated with significant toxicities and management strategies are primarily founded on clinical trial experience. This study aimed to provide an evaluation of patients receiving PARPi therapy within an academic health-system. Methods: A retrospective, observational study of adult patients with gynecologic malignancy was conducted at the University of Pennsylvania Health System. Data was collected on patients prescribed a PARPi between December 2014 and October 2019. The primary endpoint was the status of PARPi therapy at the end of the study period. Key secondary endpoints included toxicity management strategies, time to discontinuation due to toxicity, progression free survival (PFS), and overall survival (OS). Results: Of the 85 patients included, 45 (53%) received olaparib, 24 (28%) niraparib, and 16 (19%) rucaparib. Twenty-nine patients (34%) continued on therapy, 15 (18%) discontinued due to toxicity, and 41 (48%) discontinued due to progression. Fifty-one percent of patients required a dose reduction due to toxicities. The median time to discontinuation due to toxicity was 69 days (9-353). Median PFS was 181 days (9-365) and median OS was 338 days (9-365). Conclusion: PARPi therapy is associated with numerous toxicities that are best managed through a multi-modal approach. Importantly, about half the patients in the current study required a dose reduction. Overall, this observational study outlines the incidence of PARPi toxicities and reviews potential management strategies, further guiding practitioners in an area with limited real-world experience.
- Subjects
PENNSYLVANIA; OVARIAN tumors; SCIENTIFIC observation; ACADEMIC medical centers; TIME; RETROSPECTIVE studies; ANTINEOPLASTIC agents; ENDOMETRIAL tumors; DRUG therapy; PROGRESSION-free survival; ENZYME inhibitors; DRUG toxicity; MULTIHOSPITAL systems; OVERALL survival
- Publication
Journal of Oncology Pharmacy Practice, 2022, Vol 28, Issue 5, p1102
- ISSN
1078-1552
- Publication type
Article
- DOI
10.1177/10781552211024728